Seeing double at Gilead thanks to Harvoni

Gilead Sciences Inc. (NASDAQ:GILD) said its overall HCV sales increased 100% year over year, hitting $4.6 billion in 1Q15 compared to $2.3 billion in 1Q14. Sales of Harvoni ledipasvir/ sofosbuvir were $3.6 billion in 1Q15, its first full quarter on the market. Sales of Sovaldi sofosbuvir declined to $972 million in 1Q15 from $2.3 billion in 1Q14.

The company reported 1Q15 non-GAAP diluted EPS of $2.94, up 99% from $1.48 in 1Q14 and beating the Street's estimate of $2.32. Total revenues for the quarter were $7.6 billion, up 52% from $5 billion in 1Q14. Analysts were expecting $6.9 billion in revenues. ...